Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stake Raised by Nuveen Asset Management LLC

Nuveen Asset Management LLC grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 468,346 shares of the specialty pharmaceutical company’s stock after buying an additional 8,448 shares during the period. Nuveen Asset Management LLC owned 0.77% of Jazz Pharmaceuticals worth $57,677,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. LSV Asset Management raised its holdings in shares of Jazz Pharmaceuticals by 1.5% during the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company’s stock valued at $311,699,000 after buying an additional 37,108 shares during the last quarter. Pacer Advisors Inc. raised its holdings in shares of Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after buying an additional 115,102 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after buying an additional 320,724 shares during the last quarter. Capital World Investors raised its holdings in shares of Jazz Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company’s stock valued at $236,860,000 after buying an additional 104,195 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after buying an additional 315,608 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In other news, Director Seamus Mulligan acquired 1,621 shares of the stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director now owns 101,621 shares in the company, valued at approximately $10,466,963. This trade represents a 1.62% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,236 shares of company stock worth $3,956,190. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Trading Up 2.7%

Jazz Pharmaceuticals stock opened at $108.98 on Monday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of 15.35, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06. The firm’s 50 day moving average price is $115.73 and its two-hundred day moving average price is $122.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.68 EPS. On average, research analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of recent analyst reports. Morgan Stanley cut their price target on Jazz Pharmaceuticals from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th. Robert W. Baird lowered their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Truist Financial raised their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Finally, StockNews.com lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $182.79.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.